Rib-X Pharmaceuticals, a biotech developing new antibiotics for serious hospital and community infections, withdrew its plans for an initial public offering on Monday. The New Haven, CT-based company was founded in 2000 and booked $3 million in sales for the 12 months ended 12/31/2011. Deutsche Bank was set to be the bookrunner on the deal.
